---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-26-000028"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2026-09-14T20:16:45+00:00"
generated_at: "2026-09-14T20:18:33.408589+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# iBio updates corporate presentation focused on antibodies for obesity and cardiometabolic diseases

## Summary
- Corporate presentation dated September 2026 filed as Exhibit 99.1; highlights breakthrough antibodies for obesity and cardiometabolic diseases.
- No specific pipeline milestones, financial figures, or clinical data disclosed in the filing excerpt.
- Filing notes forward-looking statements and risks including regulatory approvals, financing, and Nasdaq listing maintenance.
- Presentation updated for meetings with investors, analysts, and others; no other material events reported.

## SEC filing metadata
- accession: 0001420720-26-000028
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2026-09-14T20:16:45+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072026000028/0001420720-26-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072026000028/ibio-20260914x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-26-000028
- JSON: https://secwatch.observer/filing/0001420720-26-000028.json
- Plain text: https://secwatch.observer/filing/0001420720-26-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.